Effects of oxytocin versus promestriene on genitourinary syndrome: a pilot, prospective, randomized, double-blind study
Clinics
; 77: 100116, 2022. tab, graf
Article
em En
|
LILACS-Express
| LILACS
| ID: biblio-1404333
Biblioteca responsável:
BR1.1
ABSTRACT
Abstract Objectives:
In this pilot, prospective, randomized, double-blind study, the authors compared the efficacy of oxytocin with promestriene in improving vaginal atrophy of Genitourinary Syndrome of Menopause (GSM).Methods:
A total of 51 postmenopausal women with symptoms of GSM were evaluated. They were randomized into two groups oxytocin (25 patients) and promestriene (26 patients) and were evaluated before and after 90 days of treatment; the evaluation was based on the domains of the Female Sexual Function Index (FSFI) (lubrication, satisfaction, and pain during sexual intercourse), clinical visual examination, and vaginal wall thickness.Results:
After the use of the medications, both groups showed significant improvement in the three evaluated FSFI domains (p < 0.05) and there was no significant difference between the groups (p > 0.05). On clinical examination, the medications improved all the evaluated parameters but without statistical significance (p > 0.05). The evaluation of the thickness of the vaginal epithelium showed that both treatments led to increase in the vaginal epithelium (p < 0.05); however, the efficacy of promestriene was higher than that of oxytocin (p < 0.05).Conclusions:
Both medications were effective, however, studies with larger samples and longer follow-ups are needed to confirm the clinical applicability.
Texto completo:
1
Índice:
LILACS
Tipo de estudo:
Clinical_trials
Idioma:
En
Revista:
Clinics
Assunto da revista:
MEDICINA
Ano de publicação:
2022
Tipo de documento:
Article